From mice to men: GEMMs as trial patients for new NSCLC therapies

Sarah A Hayes; Amanda L Hudson; Stephen J Clarke; Mark P Molloy; Viive M Howell

doi:10.1016/j.semcdb.2014.04.002

From mice to men: GEMMs as trial patients for new NSCLC therapies

Semin Cell Dev Biol. 2014 Mar:27:118-27. doi: 10.1016/j.semcdb.2014.04.002. Epub 2014 Apr 6.

Authors

Sarah A Hayes¹, Amanda L Hudson¹, Stephen J Clarke¹, Mark P Molloy², Viive M Howell³

Affiliations

¹ Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia.
² Australian Proteome Analysis Facility (APAF), Macquarie University, Sydney, Australia; Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, Australia.
³ Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia. Electronic address: viive.howell@sydney.edu.au.

PMID: 24718320
DOI: 10.1016/j.semcdb.2014.04.002

Abstract

Given the large socio-economic burden of cancer, there is an urgent need for in vivo animal cancer models that can provide a rationale for personalised therapeutic regimens that are translatable to the clinic. Recent developments in establishing mouse models that closely resemble human lung cancers involve the application of genetically engineered mouse models (GEMMs) for use in drug efficacy studies or to guide patient therapy. Here, we review recent applications of GEMMs in non-small cell lung cancer research for drug development and their potential in aiding biomarker discovery and understanding of biological mechanisms behind clinical outcomes and drug interactions.

Keywords: EGFR; EML4-ALK; Genetically engineered mouse model (GEMM); Kras; Lung cancer; Mouse model.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / blood
Carcinoma, Non-Small-Cell Lung / blood
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
Genetic Engineering
Humans
Lung Neoplasms / blood
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Mice, Transgenic
Molecular Targeted Therapy
Neoplasms, Experimental / blood
Neoplasms, Experimental / drug therapy
Neoplasms, Experimental / genetics
Precision Medicine

Substances

Antineoplastic Agents
Biomarkers, Tumor